Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-09-24Clinical Trial Update: A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease [Phase 2]
Phase 2a study evaluating rilapladib (SB-659032) in Alzheimer's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-09-13Clinical Trial Update: Webnovela for Hispanic Dementia Family Caregivers [NA]
A completed clinical trial update for Webnovela aimed at Hispanic dementia family caregivers; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety/tolerability of G-CSF in subjects with mild to moderate Alzheimer's disease has …
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation [NA]
A completed clinical trial investigated non-invasive brain stimulation to enhance spatial navigation in individuals with mild cognitive impa…
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: Alzheimer's Disease: Therapeutic Potential of Estrogen [Phase 2, Phase 3]
Clinical trial update evaluating the therapeutic potential of estrogen for Alzheimer’s disease in Phase 2/Phase 3 has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-08-20Clinical Trial Update: The Depression in Alzheimer's Disease Study (DIADS) [Phase 4]
A Phase 4 clinical trial update for the Depression in Alzheimer's Disease Study (DIADS) has completed; the study investigates depression in …
-
CLINICAL_TRIALS trial_result · 2018-08-10Clinical Trial Update: Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease [Phase 3]
Phase 3 clinical trial on long-term safety and tolerability of idalopirdine (Lu AE58054) as add-on to donepezil in mild-to-moderate Alzheime…
-
CLINICAL_TRIALS trial_result · 2018-08-09Clinical Trial Update: Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) [Phase 2]
Phase 2 trial results for T-817MA in mild-to-moderate Alzheimer's disease have been completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-08-07Clinical Trial Update: Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg [Phase 3]
Phase 3 trial updating the optimal dose escalation strategy to achieve high-dose donepezil 23 mg for Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2018-07-30Clinical Trial Update: Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease [Phase 1, Phase 2]
Phase 1/2 feasibility study in adults with mild to moderate Alzheimer's disease completed; results posted in 2018.
-
FDA approval · 2018-07-27FDA Approved: DONEPEZIL HYDROCHLORIDE — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved a generic version of donepezil hydrochloride for the treatment of symptoms of Alzheimer's disease under ANDA 205269 for Hisun P…
-
CLINICAL_TRIALS trial_result · 2018-07-26Clinical Trial Update: Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease [Phase 1, Phase 2]
Phase 1/2 clinical trial of CT1812 in mild to moderate Alzheimer's disease has completed.
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease [Phase 3]
Phase 3 trial of solanezumab in prodromal Alzheimer's disease was terminated; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001) [Phase 1]
First-in-human validation study of the PET tracer [18F]MK-6240 (MK-6240-001) completed in Phase 1 for Alzheimer's disease and amnestic mild …
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care [Phase 1]
This update reports the completion of a multi-centre Phase 1 trial evaluating HTL0018318 as an add-on to standard of care in Alzheimer's dis…
-
FDA approval · 2018-07-17FDA Approved: GALANTAMINE HYDROBROMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Hikma's galantamine hydrobromide, authorizing its marketing as a generic product for Alzheimer's…
-
FDA approval · 2018-07-11FDA Approved: MEMANTINE — Original Application (Chartwell RX, LLC)
FDA approved the original ANDA for memantine as a generic drug manufactured by Chartwell RX, LLC.
-
FDA approval · 2018-07-10FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
FDA approved a supplemental application for NEURACEQ (Florbetaben F-18) from Lantheus Biosciences Ltd.
-
CLINICAL_TRIALS research · 2018-07-10Clinical Trial Update: Validation of the Montreal Cognitive Assessment in Patients With Mild and Major Neurocognitive Disorder
A completed clinical trial evaluating the Montreal Cognitive Assessment for validity in patients with mild and major neurocognitive disorder…
-
CLINICAL_TRIALS trial_result · 2018-07-06Clinical Trial Update: A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease [Phase 2]
Phase 2 study evaluating Bryostatin for moderately to severely Alzheimer's disease has completed, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
This clinical trial update reports completion of a study evaluating screening and evaluation methods for patients with signs and symptoms of…
-
FDA approval · 2018-06-20FDA Approved: RIVASTIGMINE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved an original generic rivastigmine application from Mylan for treatment of dementia associated with Alzheimer's disease and Parki…
-
CLINICAL_TRIALS trial_result · 2018-06-14Clinical Trial Update: Clinical Evaluation of Florbetapir F 18 (18F-AV-45) [Phase 2]
Phase 2 clinical evaluation of Florbetapir F-18 (18F-AV-45) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2018-06-14Clinical Trial Update: Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease [NA]
A completed clinical trial assessed whether focused ultrasound with intravenous contrast agents can open the blood-brain barrier in patients…
-
CLINICAL_TRIALS trial_result · 2018-06-12Clinical Trial Update: Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment
A clinical trial update reports a favorable rate of clinical response to cholinesterase inhibitors in Alzheimer's disease after three months…